Sunil Dogra

Featured in: Favicon

medium.com Favicon

springer.com Favicon

sagepub.com Favicon

jamanetwork.com (+1) Favicon

thelancet.com Favicon

dovepress.com Favicon

mdedge.com Favicon

ijo.in + 2 more

Articles

Assessing the clinical progress of the bispecific nanobody sonelokimab

2 months ago | tandfonline.com | Sunil Dogra |Sukhdeep Singh

ABSTRACTIntroduction- Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases such as psoriasis, hidradenitis suppurativa (HS), and psoriatic arthritis. Its innovative design offers improved tissue penetration, rapid clearance, and reduced immunogenicity, addressing limitations of current monoclonal antibody therapies.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →